Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A high grade carcinoma of the kidney. It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.
Biomarker and diagnostic research for sarcomatoid renal cell carcinoma has been reported in the published literature.
14 clinical trials registered, 6 recruiting. Interventions under study include procedural interventions, biologic therapy, drug therapy, and other interventions. Pipeline includes 2 PHASE3, 5 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07128680](https://clinicaltrials.gov/study/NCT07128680) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer |
PHASE1 |
City of Hope Medical Center |
RECRUITING |
[NCT07037004](https://clinicaltrials.gov/study/NCT07037004) | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | PHASE2 | City of Hope Medical Center | RECRUITING |
[NCT06866262](https://clinicaltrials.gov/study/NCT06866262) | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | PHASE1 | University of Michigan Rogel Cancer Center | RECRUITING |
[NCT06447103](https://clinicaltrials.gov/study/NCT06447103) | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | PHASE2 | Jonsson Comprehensive Cancer Center | RECRUITING |
[NCT06399419](https://clinicaltrials.gov/study/NCT06399419) | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | PHASE1 | Osel, Inc. | RECRUITING |
50 publications have been identified in PubMed for sarcomatoid renal cell carcinoma. Research spans Case Report / Case Series (51%), Epidemiology / Natural History (14%), and Basic Science / Preclinical (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 22 | 51% |
Disease patterns and progression | 6 | 14% |
Laboratory research | 5 | 12% |
Testing and diagnosis research | 4 | 9% |
Research summaries | 3 | 7% |
Clinical study results | 2 | 5% |
New treatment approaches | 1 | 2% |
Zafar R (2026). [PMID: 32491531](https://pubmed.ncbi.nlm.nih.gov/32491531/). *Unknown Journal*. [Case Report / Case Series]
Nicolazzini M (2026). [PMID: 41899059](https://pubmed.ncbi.nlm.nih.gov/41899059/). *J Clin Med*. [Epidemiology / Natural History]
Savaris T (2026). [PMID: 41605096](https://pubmed.ncbi.nlm.nih.gov/41605096/). *J Comp Pathol*. [Case Report / Case Series]
Rathore K (2026). [PMID: 41552272](https://pubmed.ncbi.nlm.nih.gov/41552272/). *J Kidney Cancer VHL*. [Case Report / Case Series]
Tamura K (2026). [PMID: 42106902](https://pubmed.ncbi.nlm.nih.gov/42106902/). *Int J Urol*. [Epidemiology / Natural History]
Lasorsa F (2026). [PMID: 41792526](https://pubmed.ncbi.nlm.nih.gov/41792526/). *Current urology reports*. [Review / Meta-Analysis]
Phiensuparp P (2026). [PMID: 41545219](https://pubmed.ncbi.nlm.nih.gov/41545219/). *BMJ Case Rep*. [Case Report / Case Series]
Qasim H (2025). [PMID: 41426798](https://pubmed.ncbi.nlm.nih.gov/41426798/). *Cureus*. [Review / Meta-Analysis]
Liu T (2025). [PMID: 41058428](https://pubmed.ncbi.nlm.nih.gov/41058428/). *Clin Genitourin Cancer*. [Diagnostic / Biomarker]
Nusapan R (2025). [PMID: 40691018](https://pubmed.ncbi.nlm.nih.gov/40691018/). *Histopathology*. [Case Report / Case Series]